Quintiles Transnational Corp, a provider of contract research for the pharmaceutical and biotechnology industries, is speaking to banks about a potential initial public offering, writes Reuters. JPMorgan Chase and Deutsche Bank are among the banks vying for a role, writes Reuters.
Reuters – Quintiles Transnational Corp, the largest provider of contract research for the pharmaceutical and biotechnology industries, is speaking to banks about a potential initial public offering, two people familiar with the matter said on Friday.
Quintiles has held “bake-off” talks with banks this week to appoint bookrunners for an IPO, the people said on condition of anonymity because the discussions are confidential. JPMorgan Chase & Co (JPM.N) and Deutsche Bank AG (DBKGn.DE) are among the banks vying for a role, one of the people added.
Private equity firms Bain Capital LLC and TPG Capital LP became the lead investors in Quintiles in January 2008 after One Equity Partners sold its stake in the Durham, North Carolina-based company. Britain’s 3i Group Plc (III.L) and Singapore’s Temasek Holdings are also investors in Quintiles.
“Quintiles routinely evaluates its capital strategy, and it is our policy not to comment on these matters,” Quintiles spokesman Phil Bridges said.
Bain and TPG declined to comment while 3i and Temasek did not immediately respond to a request for comment. JPMorgan declined to comment and Deutsche Bank did not respond to a request for comment.
Regulatory filings from publicly listed 3i show that the private equity firm valued its 7 percent stake in Quintiles at 109 million pounds at the end of March 2009, implying an equity value for Quintiles of 1.56 billion pounds ($2.46 billion).
By the end of March 2012, 3i valued its stake, that had dropped to 4.9 percent, at 86 million pounds, implying an equity value for Quintiles of 1.76 billion pounds ($2.77 billion). Nevertheless, an IPO could value the company substantially above or below such mark-to-market estimates.
Quintiles refinanced a $2 billion loan in December on more favorable terms and also took on $475 million in new debt earlier in 2012 to pay dividends to its private equity owners, according to notes by credit rating agencies.
Quintiles relies on pharmaceutical companies outsourcing more of their non-core research functions. It recorded net service revenue of about $3.5 billion for the 12 months to the end of June 2012, according to Moody’s Investors Service Inc.
Private equity-backed IPOs have put in a strong showing since the start of the year, prompting more buyout firms to consider a stock market flotation as a way to exit their investment.
On Thursday, another IPO of a Bain-backed company, Bright Horizons Family Solutions Inc (BFAM.N), raised $222 million. Investors drove the shares of the company, which is the largest U.S. child-care provider, up as much as 30 percent in its first day of trading.
Last week, cruise line operator Norwegian Cruise Line Holdings Ltd’s (NCLH.O) shares rose 32 percent in their stock market debut following an IPO of the company, which counts TPG and Apollo Global Management LLC (APO.N) among its investors.
Bloomberg News reported on the discussions between Quintiles and the banks about an IPO earlier on Friday.
(Reporting by Greg Roumeliotis in New York; Editing by Bernard Orr)
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.